Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Am J Ophthalmol. 2020 Mar 12;213:153–160. doi: 10.1016/j.ajo.2020.01.025

Table 3.

Variables Affecting Cataract and/or Dry Eye Syndrome Development

Cataract Dry Eye

Variable HRa 95% CI Pb HR 95% CI P
Age at Transplantation 0.9 0.8361–0.9654 0.0035 1.2 1.0741.267 0.00026
Age at Cancer Diagnosis 0.96 0.9185–0.9992 0.046 1 0.9803–1.106 0.19
Dose of Total Body Irradiation 1 1.001–1.002 <0.001 1 0.99890.9998 0.0029
Dose of Head/Neck Radiation 1 0.9998–1.001 0.33 1 0.9996–1.001 0.51
Dose of Non-Head/Neck Radiation 1 0.9996–1.001 0.28 1 0.9994–1.001 0.68
Gender: Male 1.3 0.7797–2.257 0.3 0.94 0.5491–1.609 0.82
Race: Other 3.5 0.9293–13.1 0.064 0.96 0.4574–2.009 0.91
Race: White 4.9 1.556–15.43 0.0066 0.75 0.37161.507 0.42
Nonmalignant Disease 0.19 0.06523–0.5448 0.0021 1.3 0.69752.325 0.43
Sibling Donor 1.2 0.492–3.044 0.66 0.52 0.2486–1.097 0.086
Unrelated Donor 2.3 0.9423–5.406 0.068 0.34 0.1492–0.789 0.012
Survival: Deceased 0.95 0.3017–2.998 0.93 1.2 0.3684–3.941 0.76
Product Type: Cord blood 7.00E-05 1.45E-05–0.000337 0 0.93 0.08214–10.61 0.96
Product Type: Marrow 1.8 0.796–3.881 0.16 0.35 0.1967–0.6276 0.00041
Cytomegalovirus-Positive Recipient 0.45 0.2632–0.7828 0.0045 1.1 0.63481.906 0.73
Steroid Use 0.61 0.3065–1.215 0.16 3.5 1.974–6.132 <0.001
Calcineurin Inhibitor Use 1.2 0.4844–2.78 0.74 1.3 0.5418–3.256 0.53
Acute Graft-versus-Host Disease 0.83 0.4841–1.412 0.49 1.6 0.9487–2.826 0.077
Chronic Graft-versus-Host Disease 0.72 0.3537–1.469 0.37 3.5 2.045–5.967 <0.001
Total Body Irradiation 5.6 2.302–13.41 0.00014 0.48 0.27230.8371 0.0099
Busulfan Use 0.6 0.1993–1.797 0.36 1.2 0.6129–2.416 0.57
Cyclophosphamide Use 2.5 0.8398–7.18 0.1 0.28 0.1388–0.5851 0.00063
Cytarabine Use 3 1.812–5.045 <0.001 0.25 0.13460.4694 <0.001
Fludarabine Use 0.26 0.07598–0.8755 0.03 3.4 1.7776.539 0.00023
Melphalan Use 0.26 0.05969–1.148 0.076 7.2 3.52614.58 <0.001
Thiotepa Use 0.68 0.3813–1.206 0.19 3 1.681–5.477 0.00023
Conditioning Treatment: Chemotherapy only 0.1 0.01379–0.7778 0.028 0.99 0.37162.643 0.99
Conditioning Treatment: None 0.21 0.08074–0.5519 0.0015 2.9 1.5735.468 0.00071
a

Abbreviations: CI, confidence interval; HR, hazard ratio

b

Statistically significant values are in bold.